Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Top Cited Papers
- 1 November 2002
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 13 (16), 1935-1943
- https://doi.org/10.1089/10430340260355347
Abstract
Recombinant adeno-associated viruses (rAAV) are produced transiently in mammalian cells usually by cotransfecting two or three plasmids containing AAV genes, adenovirus helper genes, and a vector genome. Expansion and transfection of adherent cells limit the scale of rAAV production. Efficient transfection is performed with cells on solid support media such as tissue culture plates. A large animal study or a human clinical trial may require 10(15) particles of vector, depending on dose. To generate this quantity of rAAV by transfection, more than 10(11) HEK293 cells may be needed, which would require about 5000 x 175 cm(2) flasks. The ability to scale up rAAV production by these methods severely restricts the commercialization and use of AAV vectors. A recombinant baculovirus derived from the Autographa californica nuclear polyhedrosis virus is widely employed for large-scale production of heterologous proteins in cultured insect cells and may provide an attractive alternative. Toward this goal, we have explored the production of rAAV in invertebrate cells. Sf9 cells may be coinfected in suspension cultures with three recombinant baculoviruses (a Rep-baculovirus, a VP-baculovirus, and an AAV ITR vector genome baculovirus) and, 3 days later, rAAV is recovered. The particles produced are indistinguishable from 293 cell-produced rAAV, as determined on the basis of physical properties and biologic activities. Particles produced by either method were composed of similar proteins and nucleic acid. The yield of genome-containing particles produced per Sf9 cell approached 5 x 10(4), thus, 1000 ml of cultured Sf9 cells produced the equivalent of between 500 to 1000 x 175 cm(2) flasks of 293 cells. This robust system provides a simple, cost-effective method for AAV vector production.Keywords
This publication has 34 references indexed in Scilit:
- Recent advances in recombinant adeno-associated virus vector productionKidney International, 2002
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Novel Tools for Production and Purification of Recombinant Adenoassociated Virus VectorsHuman Gene Therapy, 1998
- High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle VirusHuman Gene Therapy, 1998
- Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsNature Genetics, 1997
- High-Efficiency Transfer of the T Cell Co-Stimulatory Molecule B7-2 to Lymphoid Cells Using High-Titer Recombinant Adeno-Associated Virus VectorsHuman Gene Therapy, 1995
- Cell Lines for the Production of Recombinant Adeno-Associated VirusHuman Gene Therapy, 1995
- Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brainNature Genetics, 1994
- Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene TherapyHuman Gene Therapy, 1994
- Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian CellsPublished by Springer Science and Business Media LLC ,1992